NcXHF

PERFUSION AND INFUSION IN THE ERA OF EFFECTIVE SYSTEMIC THERAPY
fıt. A phase II trial protocol is presently open for recruitment
combining ILP and systemic ipilimumab (NCT02094391).
In conclusion, ILI and ILP are here to stay. The procedures
provide rapid responses that are still superior to the responses
achieved by systemic therapy, even in the latest trials. The responses
are obtained at the cost of only very mild local, and virtually
absent, systemic toxicity. Patients with extensive IT-mets
do need local treatment for disease control, but as unresectable
stage III disease is a reflection of poor tumor biology, survival
remains relatively poor. We fırmly believe that this provides a
massive opportunity for systemic agents. The results of the combination
trials are awaited with great expectations.
Disclosures of Potential Conflicts of Interest
Relationships are considered self-held and compensated unless otherwise noted. Relationships marked “L” indicate leadership positions. Relationships marked “I” are those held by an immediate
family member; those marked “B” are held by the author and an immediate family member. Institutional relationships are marked “Inst.” Relationships marked “U” are uncompensated.
Employment: None. Leadership Position: None. Stock or Other Ownership Interests: None. Honoraria: Cornelis Verhoef, Roche. Consulting or Advisory
Role: Cornelis Verhoef, Roche. Speakers’ Bureau: None. Research Funding: None. Patents, Royalties, or Other Intellectual Property: None. Expert
Testimony: None. Travel, Accommodations, Expenses: None. Other Relationships: None.
References
1. SEER Stat Fact Sheets. Melanoma of the skin. http://seer.cancer.gov/
statfacts/html/melan.html. Accessed February 12, 2015.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC
melanoma staging and classifıcation. J Clin Oncol. 2009;27:6199-6206.
3. Creech O Jr, Krementz ET, Ryan RF, et al. Chemotherapy of cancer:
regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;
148:616-632.
4. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma:
effectiveness and toxicity of cisplatin compared with that of melphalan
and other drugs. World J Surg. 1992;16:227-233.
5. Omlor G. Optimization of isolated hyperthermic limb perfusion. World
J Surg. 1993;17:134.
6. Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of
cancer cells. Biochemical and clinical studies. Cancer. 1967;20:1351-1381.
7. Clark J, Grabs AJ, Parsons PG, et al. Melphalan uptake, hyperthermic
synergism and drug resistance in a human cell culture model for the
isolated limb perfusion of melanoma. Melanoma Res. 1994;4:365-370.
8. Di Filippo F, Anzà M, Rossi CR, et al. The application of hyperthermia
in regional chemotherapy. Semin Surg Oncol. 1998;14:215-223.
9. Kroon BB, Klaase JM, van Geel AN, et al. Application of hyperthermia
in regional isolated perfusion for melanoma of the limbs. Reg Cancer
Treat. 1992;4:223-226.
10. Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-fıve years of isolated
limb perfusion for melanoma: indications and results. Br J Surg. 1996;
83:1319-1328.
11. Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic,
isolated limb perfusion for melanoma: a reflection of tumor biology.
Ann Surg. 2007;245:591-596.
12. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor
that causes necrosis of tumors. Proc Natl Acad Sci USA.1975;72:
3666-3670.
13. Sugarman BJ, Aggarwal BB, Hass PE, et al. Recombinant human tumor
necrosis factor-alpha: effects on proliferation of normal and transformed
cells in vitro. Science. 1985;230:943-945.
14. Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of tumor necrosis
factor on tumor vasculature in mice. Cancer Res. 1988;48:2179-2183.
15. Feldman ER, Creagan ET, Schaid DJ, et al. Phase II trial of recombinant
tumor necrosis factor in disseminated malignant melanoma. Am J Clin
Oncol. 1992;15:256-259.
16. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenouslyadministered
recombinant tumor necrosis factor-alpha in cancer patients.
J Clin Oncol. 1988;6:1328-1334.
17. Asher A, Mulé JJ, Reichert CM, et al. Studies on the anti-tumor effıcacy
of systemically administered recombinant tumor necrosis factor against
several murine tumors in vivo. J Immunol. 1987;138:963-974.
18. Watanabe N, Niitsu Y, Umeno H, et al. Synergistic cytotoxic and antitumor
effects of recombinant human tumor necrosis factor and hyperthermia.
Cancer Res. 1988;48:650-653.
19. Regenass U, Müller M, Curschellas E, et al. Anti-tumor effects of tumor
necrosis factor in combination with chemotherapeutic agents. Int J Cancer.
1987;39:266-273.
20. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor
necrosis factor alpha in combination with interferon gamma and
melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
J Clin Oncol. 1992;10:52-60.
21. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion
for localized, high-risk limb melanoma: results of a multicenter randomized
phase III trial. European Organization for Research and Treatment
of Cancer Malignant Melanoma Cooperative Group Protocol
18832, the World Health Organization Melanoma Program Trial 15,
and the North American Perfusion Group Southwest Oncology Group-
8593. J Clin Oncol. 1998;16:2906-2912.
22. Olofsson Bagge R, Mattsson J, Hafström L. Regional hyperthermic perfusion
with melphalan after surgery for recurrent malignant melanoma
of the extremities-long-term follow-up of a randomised trial. Int J Hyperthermia.
2014;30:295-298.
23. Klaase JM, Kroon BB, van Geel AN, et al. A retrospective comparative
study evaluating the results of a single-perfusion versus doubleperfusion
schedule with melphalan in patients with recurrent melanoma
of the lower limb. Cancer. 1993;71:2990-2994.
24. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Long-term results of a
double perfusion schedule using high dose hyperthermia and melphalan
sequentially in extensive melanoma of the lower limb. Melanoma
Res. 2003;13:395-399.
25. Thompson JF, Kam PC, Waugh RC, et al. Isolated limb infusion with
cytotoxic agents: a simple alternative to isolated limb perfusion. Semin
Surg Oncol. 1998;14:238-247.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e533